Vitamin D status was not associated with 'one-year' progression of coronary artery disease, assessed by coronary angiography in statin-treated patients.
BACKGROUND
Low vitamin D status is associated with increased risk of cardiovascular disease and may be involved in atherosclerosis. Our aim was to assess the association between vitamin D status and the progression of coronary artery disease (CAD).


RESULTS
We measured 25-hydroxyvitamin D3 (25OHD3) by liquid chromatography tandem mass spectrometry (LC-MS/MS) in plasma from 348 participants with established CAD (84% males, mean ± standard deviation (SD) age 60 ± 10 years) of the Western Norway B-vitamin Intervention Trial (WENBIT, 1999-2006). The patients underwent invasive coronary angiography (CA) and percutaneous coronary intervention at baseline and a second CA after 302 ± 79 days of follow-up. From the angiograms, minimal lumen diameter (MLD) and diameter stenosis (DS) of atherosclerotic lesions were obtained. Significant CAD in non-intervened vessels was found in 309 coronary arteries from 183 participants either at baseline and/or at follow-up. To assess the association between levels of 25OHD3 and CAD progression in non-intervened vessels, we applied a linear quantile fitted mixed effects model with MLD or DS measured at follow-up as a function of continuous 25OHD3 concentrations. There were no statistically significant associations between plasma 25OHD3 concentrations (median: 63.9, 95% confidence interval (CI): 48.1-78.5 nmol/l) measured at baseline and the follow-up measures of either MLD (estimated effect per 10 nmol/l increase of 25OHD3 and 95% CI: -0.015 (-0.032-0.002) mm, p = 0.088) or DS (0.225 (-0.354-0.804) percentage points, p = 0.444). Multivariate adjustment did not alter these results.


CONCLUSIONS
Plasma 25OHD3 levels were not associated with 'one-year' progression of CAD, assessed by CA in statin-treated patients.
Department of Clinical Medicine, University of Bergen, Norway eirik.degerud@k1.uib.no.
Eirik
E
Degerud
Department of Clinical Science, University of Bergen, Norway.
Kjetil H
KH
Løland
Department of Clinical Science, University of Bergen, Norway Department of Heart Disease, Haukeland University Hospital, Norway.
Ottar
O
Nygård
Bevital AS, Norway.
Øivind
Ø
Midttun
Department of Clinical Science, University of Bergen, Norway Laboratory of Clinical Biochemistry, Haukeland University Hospital, Norway.
Per M
PM
Ueland
Department of Heart Disease, Haukeland University Hospital, Norway.
Reinhard
R
Seifert
Department of Clinical Science, University of Bergen, Norway.
Elin
E
Strand
Department of Heart Disease, Haukeland University Hospital, Norway.
Øivind
Ø
Bleie
Department of Clinical Medicine, University of Bergen, Norway.
Jutta
J
Dierkes
D000368:Aged; D002112:Calcifediol / Q000097:blood*; D002853:Chromatography, Liquid; D017023:Coronary Angiography / Q000379:methods*; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy; D018450:Disease Progression; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D053719:Tandem Mass Spectrometry; D014815:Vitamins / Q000097:blood*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014815:Vitamins; D002112:Calcifediol
25-hydroxyvitamin D; Vitamin D; atherosclerosis; calcifediol; coronary angiography; coronary artery disease; disease progression